Aurum Biosciences Attending Biotech Showcase in San Francisco
Aurum Biosciences Ltd (www.aurumbiosciences.com), a company which has developed an innovative technology with the potential to save and improve the lives of thousands of people who’ve had a stroke, will be attending the Biotech Showcase event in San Francisco between the 8th – 10th January, 2018. CEO Jim McGuire and Executive Chairman Gerry McGettigan will be discussing Aurum’s forthcoming phase 2 stroke trial of its lead product ABL-101, which has recently received regulatory approval from UK regulatory authority (MHRA). They will also discuss future opportunities for further development and investment.
Aurum’s ABL-101 stroke technology is based on an oxygen carrying perflurocarbon (PFC), which is emulsified for intravenous use. This PFC not only acts as a stroke therapeutic, delivering oxygen beyond the stroke clot, but due to its effect on local oxygenation and in combination with MRI imaging, it is able to detect tissue under metabolic stress. Thus, ABL-101 has unique dual benefits of reducing brain cell death following acute stroke, while also providing important information guiding the use of further stroke treatments (Aurum preclinical data in press). Future trials will investigate the effect of ABL-101 on stroke-induced disability both in the overall stroke population, and in thrombectomy patients. The latter is an extremely interesting sub-population of stroke patients in which there have been highly promising recent clinical developments, and which may provide a more rapid route to market for novel stroke therapies.
Stroke is the second biggest killer worldwide with 1 in 6 people having a stroke by the age or 75. Every two seconds someone in the world will have a stroke. Approximately 15 million worldwide suffer an AIS annually, with the global burden continuing to rise (WHO). However, there is only one authorised medicine to treat acute stroke (alteplase, or rtPA), unlike the dozens of products available to treat other major diseases such as cancer or heart disease. To date, spending on stroke research and development has been low in the UK, with only £48 spent on research per stroke patient, compared to £241 spent on cancer. [State of Nation -Stroke Statistics 2017]
The worldwide acute stroke market was valued at $21.5 billion in 2015 and is forecast to reach $31 billion by 2021 [Zion Research].
Aurum Biosciences Ltd (www.aurumbiosciences.com) is a clinical stage biopharmaceutical company developing novel therapeutics and diagnostics. The company’s lead technology, for AIS and potentially other life-threatening and serious conditions, was conceived by inventor and Aurum Chief Scientific and Medical Officer Dr Celestine Santosh. Follow-on indications include heart disease, cancer, epilepsy, and dementia. Aurum Biosciences, headed by a team of experts in the field, has already taken the stroke management product ABL-101 through preclinical development and, having received UK regulatory approval, will be starting a phase 2 trial in stroke patients in Q1 2018.
Company contact: e-mail: email@example.com